| Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA–liposome complexes GJ Nabel, D Gordon, DK Bishop, BJ Nickoloff, Z Yang, A Aruga, ... Proceedings of the National Academy of Sciences 93 (26), 15388-15393, 1996 | 308 | 1996 |
| Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. AE Chang, A Aruga, MJ Cameron, VK Sondak, DP Normolle, BA Fox, ... Journal of clinical oncology 15 (2), 796-807, 1997 | 225 | 1997 |
| Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. A Aruga, E Aruga, K Tanigawa, DK Bishop, VK Sondak, AE Chang Journal of immunology (Baltimore, Md.: 1950) 159 (2), 664-673, 1997 | 158 | 1997 |
| Clinical utilization of postoperative dendritic cell vaccine plus activated T‐cell transfer in patients with intrahepatic cholangiocarcinoma K Shimizu, Y Kotera, A Aruga, N Takeshita, K Takasaki, M Yamamoto Journal of Hepato‐Biliary‐Pancreatic Sciences 19 (2), 171-178, 2012 | 113 | 2012 |
| Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. MJ Arca, JC Krauss, A Aruga, MJ Cameron, S Shu, AE Chang Cancer gene therapy 3 (1), 39-47, 1996 | 95 | 1996 |
| Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer A Aruga, N Takeshita, Y Kotera, R Okuyama, N Matsushita, T Ohta, ... Journal of translational medicine 12, 1-11, 2014 | 90 | 2014 |
| Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract … A Aruga, N Takeshita, Y Kotera, R Okuyama, N Matsushita, T Ohta, ... Clinical cancer research 19 (8), 2224-2231, 2013 | 87 | 2013 |
| Correlation between expression of MUC1 core protein and outcome after surgery in mass‐forming intrahepatic cholangiocarcinoma N Matsumura, M Yamamoto, A Aruga, K Takasaki, M Nakano Cancer 94 (6), 1770-1776, 2002 | 79 | 2002 |
| Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study N Suzuki, S Hazama, H Iguchi, K Uesugi, H Tanaka, K Hirakawa, A Aruga, ... Cancer science 108 (1), 73-80, 2017 | 71 | 2017 |
| Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression A Aruga, E Aruga, MJ Cameron, AE Chang Journal of Leukocyte Biology 61 (4), 507-516, 1997 | 66 | 1997 |
| Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients R Okuyama, A Aruga, T Hatori, K Takeda, M Yamamoto Oncoimmunology 2 (11), e27010, 2013 | 64 | 2013 |
| Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma K Shimizu, Y Kotera, A Aruga, N Takeshita, S Katagiri, S Ariizumi, ... Human Vaccines & Immunotherapeutics 10 (4), 970-976, 2014 | 62 | 2014 |
| Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy S Ohno, R Okuyama, A Aruga, H Sugiyama, M Yamamoto Anticancer research 32 (6), 2263-2269, 2012 | 57 | 2012 |
| Interferon-γ-Inducing Factor Elicits Antitumor Immunity Association with Interferon-γ Production J Tan, BE Crucian, AE Chang, E Aruga, A Aruga, SE Dovhey, K Tanigawa, ... Journal of Immunotherapy 21 (1), 48-55, 1998 | 57 | 1998 |
| Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization A Aruga, K Yamauchi, K Takasaki, T Furukawa, F Hanyu International journal of cancer 49 (1), 19-24, 1991 | 50 | 1991 |
| Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph … A Aruga, S Shu, AE Chang Cancer Immunology, Immunotherapy 41, 317-324, 1995 | 48 | 1995 |
| Immunological monitoring of anticancer vaccines in clinical trials C Ogi, A Aruga Oncoimmunology 2 (8), e26012, 2013 | 45 | 2013 |
| Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy I Haruta, K Yamauchi, A Aruga, T Komatsu, K Takasaki, N Hayashi, ... Journal of Immunotherapy 19 (3), 218-223, 1996 | 43 | 1996 |
| Synthesis of pyrophosphate-containing compounds that stimulate VγVδ2 T cells: application to cancer immunotherapy Y Tanaka, H Kobayashi, T Terasaki, H Toma, A Aruga, T Uchiyama, ... Medicinal Chemistry 3 (1), 85-99, 2007 | 40 | 2007 |
| Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity A Aruga, K Tanigawa, E Aruga, H Yu, AE Chang Cancer Gene Therapy 6 (1), 89-95, 1999 | 36 | 1999 |
